Germany · Delayed Price · Currency is EUR Evotec SE Earnings Call Transcripts
Fiscal Year 2025
-
2025 saw strong execution, cost savings, and a strategic pivot to higher-margin, technology-driven growth, with Just - Evotec Biologics and key partnerships driving performance. The Horizon transformation aims for EUR 75 million in savings by 2027, with recovery and margin expansion expected from H2 2026 onward.
-
Q1 2025 results were mixed, with group revenue down 4% year-over-year due to a soft shared R&D market, but Just Evotec Biologics outperformed expectations. Strategic collaborations, cost-saving measures, and a diversified customer base support a stable outlook, with full-year guidance reaffirmed.
Fiscal Year 2024
-
2024 was a transformative year, with flat group revenues and strong growth in biologics offsetting declines in Shared R&D. Cost-saving initiatives and new strategic partnerships improved liquidity and set the stage for a profit uplift in Q4, with 2024 guidance reaffirmed.
-
Revenue grew 2% in H1 2024, driven by Just – Evotec Biologics, but profitability declined due to high fixed costs and ramp-up expenses. Revised 2024 guidance reflects delayed market recovery, with cost savings and strategic transformation underway to restore growth and margins.